Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NIOX GroupCSSPF +9.62%81 EV-to-Revenue is 6.01 as of Sep. 21, 2026, which is 12% above its 10-year median of 5.39. GuruFocus rates CSSPF with a GF Score™ of 81/100 and a GF Value™ of $1.24 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 818 Medical Devices & Instruments companies, NIOX Group ranks worse than 71.64% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NIOX Group's enterprise value is $385.46 Mil.
NIOX Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $64.15 Mil. Therefore, NIOX Group's EV-to-Revenue for today is 6.01.
The historical rank and industry rank for NIOX Group's EV-to-Revenue or its related term are showing as below:
CSSPF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.24 Med: 5.39 Max: 9.72
Current: 6.01
During the past 13 years, the highest EV-to-Revenue of NIOX Group was 9.72. The lowest was 0.24. And the median was 5.39.
CSSPF's EV-to-Revenue is ranked worse than 71.64% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.89
vs CSSPF: 6.01
As of today (2026-09-21), NIOX Group's stock price is $0.8989.
NIOX Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15. Therefore, NIOX Group's PS Ratio for today is 5.99.
NIOX Group's share price for today is $0.8989.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group EV-to-Revenue Related Terms
NIOX Group EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for NIOX Group's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group EV-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where NIOX Group's EV-to-Revenue falls into.
NIOX Group's current Enterprise Value is $385.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $64.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a EV-to-Revenue of 6.01 as of Sep. 21, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on NIOX Group and its competitors. This is 12% above median its historical median of 5.39. Over the past decade, NIOX Group's EV-to-Revenue has ranged from 0.24 to 9.72. According to the industry distribution chart, NIOX Group ranks #586 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 71.6%.
Is NIOX Group's EV-to-Revenue too high?
NIOX Group's current EV-to-Revenue of 6.01 is 12% above median its 10-year median of 5.39. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 9.72. The Medical Devices & Instruments industry median EV-to-Revenue is 2.89. NIOX Group's value of 6.01 is 108% above this industry median. Based on the distribution chart, NIOX Group ranks #586 out of 818 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's EV-to-Revenue compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #586 out of 818 companies for EV-to-Revenue. This places NIOX Group in the lower half of its industry. The industry median EV-to-Revenue is 2.89. NIOX Group's value of 6.01 is 108% above this benchmark. Historically, NIOX Group's own EV-to-Revenue has ranged from 0.24 to 9.72 over the past decade. While the company's 10-year median is 5.39 vs. the industry median of 2.89, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Devices & Instruments company?
The median EV-to-Revenue among Medical Devices & Instruments companies is 2.89, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current EV-to-Revenue of 6.01 is 108% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-Revenue is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current EV-to-Revenue is 6.01, which is 12% above median its own 10-year median of 5.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.24, compared to a current price of $0.90 — trading 27.5% below its estimated fair value. The current EV-to-Revenue is 6.01, which is 12% above median its 10-year median of 5.39 and 108% above the Medical Devices & Instruments industry median of 2.89. NIOX Group's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For NIOX Group (CSSPF), the current EV-to-Revenue is 6.01 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.90 is trading 27.5% below its estimated GF Value™ of $1.24.
GuruFocus considers NIOX Group to be Modestly Undervalued.
Key valuation signals for CSSPF:
EV-to-Revenue: 6.01 (12% above median its 10-year median of 5.39)
GF Value™: $1.24 vs. price of $0.90 (27.5% below fair value)
Industry Position: 108% above the Medical Devices & Instruments median (#586 of 818)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
81GF Score
Get the complete analysis for CSSPF
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
